Lung airflow

Lung airflow refers to the physiological process of air moving into and out of the lungs, driven by pressure gradients between the atmosphere and the alveoli [1]. It is not a molecular target such as a protein or receptor, but rather a complex physiological outcome regulated by airway diameter, lung compliance, and the activity of respiratory muscles [1, 2]. In clinical practice, lung airflow is measured using spirometry, with parameters like Forced Expiratory Volume in 1 second (FEV1) serving as primary endpoints for respiratory health and drug efficacy [3]. Impairment of airflow is a defining characteristic of obstructive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD), where increased airway resistance limits effective ventilation [2, 4]. Pharmacological treatments do not bind to airflow itself; instead, they target molecular entities like the beta-2 adrenergic receptor or muscarinic M3 receptors to relax airway smooth muscle and improve flow [4, 5]. Consequently, while lung airflow is a vital therapeutic objective and clinical biomarker, it does not meet the criteria for a discrete molecular drug target [1, 5]. Citations: [1] StatPearls, Physiology, Airflow Resistance (2023); [2] NIH, How the Lungs Work (2022); [3] Mayo Clinic, Spirometry (2023); [4] Global Initiative for Asthma (GINA), Global Strategy for Asthma Management and Prevention (2023); [5] American Thoracic Society, Standardization of Spirometry (2019).

Other names

Pulmonary ventilationAirflowRespiratory flowVentilationAirway flow

Improvement of airflow via bronchodilation (relaxation of airway smooth muscle) or reduction of airway inflammation and mucus secretion to decrease airway resistance.